Pricing Log in Create free account

Vir Biotechnology, Inc. (VIR) vs Zymeworks Inc. (ZYME)

Vir Biotechnology, Inc. and Zymeworks Inc. are both Biotechnology companies. Vir Biotechnology, Inc. and Zymeworks Inc. are of similar size ($2.3B and $2.2B). Vir Biotechnology, Inc. has negative trailing earnings, so its P/E is not meaningful; Zymeworks Inc. trades at 43.7×. Vir Biotechnology, Inc. grew revenue faster over the last twelve months: 1,696.0% against 97.8%. Zymeworks Inc. has the higher net margin (16.3% vs −61.0%) and the higher return on invested capital (17.5% vs −30.3%). Across the 17 metrics below, Zymeworks Inc. leads on 10 and Vir Biotechnology, Inc. on 7.

Valuation

Metric VIR ZYME Biotechnology median
P/E n/m 43.69 11.58
P/S 7.33 7.83 9.61
P/B 2.48 8.06 2.26
Price to free cash flow n/m n/m 26.41
EV/EBITDA n/m 36.88 0.72
EV/Sales 5.81 7.45 9.43
Earnings yield (9.52%) 2.29% (32.28%)
Free cash flow yield (6.39%) (5.46%) (22.27%)

Profitability

Metric VIR ZYME Biotechnology median
Gross margin 99.99% 51.40% 68.81%
Operating margin (69.82%) 16.60% 0.00%
Net margin (61.03%) 16.28% 0.00%
Free cash flow margin (46.87%) (42.42%) 0.00%
Return on equity (21.84%) 14.98% (50.30%)
Return on assets (17.34%) 5.50% (45.47%)
Return on invested capital (30.32%) 17.49% 0.00%

Growth

Metric VIR ZYME Biotechnology median
Revenue growth (TTM) 1,695.96% 97.78% 6.78%
EPS growth (last fiscal year) 17.49% 33.33% 29.88%
Revenue growth, 5-year CAGR (2.14%) 22.16% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric VIR ZYME Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 6.30 3.30 4.74
Net debt to EBITDA 1.02 2.81 1.01

Dividend

Metric VIR ZYME Biotechnology median
Dividend yield — — 0.39%
Payout ratio — — —

Size

Metric VIR ZYME Biotechnology median
Market cap 2.25b 2.23b 168.63m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack